Company Filing History:
Years Active: 1998-2004
Title: The Innovative Contributions of Gilles Caille
Introduction
Gilles Caille is a notable inventor based in Outremont, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of deuterated drugs. With a total of three patents to his name, Caille's work has the potential to enhance drug efficacy and safety.
Latest Patents
Caille's latest patents include a method of using deuterated calcium channel blockers. This method enhances the efficiency and increases the duration of action of drugs such as dihydropyridines and anti-bacterials, specifically nifedipine and penicillins. The innovation involves deuterating one or more hydrogen atoms in the drug, resulting in unexpectedly improved properties when used in much lower concentrations than the unmodified drug. Additionally, he has developed a method for determining the identity and bioequivalency of a new drug. This method utilizes isotope ratio mass spectrometry to compare the molecular and isotope structure of a new drug with that of a known human drug.
Career Highlights
Gilles Caille is associated with Isotechnika Inc., a company focused on innovative drug development. His work has been instrumental in advancing the understanding of drug interactions and improving therapeutic outcomes.
Collaborations
Caille has collaborated with notable colleagues such as Robert T Foster and Richard Lewanczuk. These partnerships have contributed to the success of his research and the development of his patents.
Conclusion
Gilles Caille's innovative work in the field of pharmaceuticals demonstrates the importance of research and development in enhancing drug efficacy. His contributions have the potential to significantly impact the medical community and improve patient outcomes.